Arcellx reports Q4 revenue $63.1M, consensus $15.68M

Q4 net income was $20.5M vs. ($39.0M) last year. As of December 31, 2023, Arcellx had cash, cash equivalents, and marketable securities of $729.2M, which Arcellx expects to fund its operations into 2027 “In 2023, our team built upon the momentum that has propelled Arcellx forward over the past two years,” said CEO Rami Elghandour. “We expanded our partnership with Kite, through a $200M investment, extending our cash runway into 2027 and deepened our collaboration by expanding into lymphomas. Additionally, we presented robust long-term data from our Phase 1 expansion study of anito-cel at the 65th ASH Annual Meeting..This year is poised to be another year of meaningful progress for our organization. We are focused on completing enrollment in the iMMagine-1 trial, initiating our clinical trial in earlier lines of multiple myeloma, and completing the technical transfer to Kite…We believe that with our technology coupled with Kite’s recognized global leadership and established manufacturing expertise, we are well positioned to achieve this goal. Additionally, we continue to invest in research and believe the differentiation of the D-Domain technology provides an opportunity for us to expand our development pipeline in other therapeutic areas.”